

## BIBLIOGRAPHY

## BIBLIOGRAPHY

- Alleva, D.G., C.J. Burger and K.D. Elgert. 1994. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF- $\alpha$  production : role of tumor-derived IL-10, TGF- $\beta$  and prostaglandin E<sub>2</sub>. *J. Immunol.* 153: 1674.
- Anaclerio, A.A., J.D. Waterfield, G. Moller. 1974. Induction of lymphocyte mediated cytotoxicity against allogeneic tumour cells by Concanavalin A *in vivo*. *J. Immunol.* 113: 870.
- Anderson, J., G.M. Edelman, G. Moller and O. Sjogberg. 1972. Activation of B lymphocytes by locally concentrated concanavalin A. *Eur. J. Immunol* 2: 233.
- Arai, S., H. Yamamoto, K. Itoh and K. Kumagai. 1983. Suppressive effect of human natural killer cells on pokeweed mitogen-induced B cell differentiation. *J. Immunol.* 131: 651.
- Belldegrun, A., D.E. Webb, H.J. Austin, S.M. Steinberg, D.E. White, W.M. Lineham and S.A. Rosenberg. 1987. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. *Ann Int. Med.* 106: 817.
- Bellone, G., N. M. Valiante, B. Viale, E. Ciccone, L. Moretta, G. Trinchieri. 1993. Regulation of hematopoiesis *in vitro* by alloreactive natural killer cell clones. *J. Exp Med.* 177: 1117.
- Bergelson. L.D., E.V. Dyatlovitskaya, T.E. Klyuchareva, E.V. Kryukova, A.F. Lemenovskaya, V.A. Matveeva

- and E.V. Sinitsyna. 1989. The role of gangliosides in natural immunity. Gangliosides modulate the cytotoxicity of natural killer cells. *Eur. J. Immunol.* 19: 1979.
- Bezouska K., C. T. Yuen, J. O'Brien, R.A. Childs, W. Chai, A.M. Lawson, K Drbal, A. Firerova, M. Pospisil, T. Feizi. 1994. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. *Nature.* 372: 150.
- Biron, C.A., P. Van Den Elsen, M.M. Tutt, P. Medvezky, V. Kumar and C. Terhorst. 1987. Murine Natural Killer cells stimulated *in vivo* do not express the T cell receptor  $\alpha, \beta, \gamma, T3\delta$  or T3 $\epsilon$  genes. *J. Immunol.* 139: 1704.
- Biron, C.A., H.A. Young and M.T. Kasaian. 1990. Interleukin-2-induced proliferation of murine Natural killer cells *in vivo*. *J. Exp. Med.* 171: 173.
- Brooks, C. G., R. C. Rees and R. H. Leach. 1979. High nonspecific reactivity of normal lymphocytes against mycoplasma-infected target cells in cytotoxicity assays. *Eur. J. Immunol.* 9: 159.
- Brunda, M.J., L. Luistro, R.R. Warriar, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf and M.K. Gately. 1994. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. *J. Exp Med.* 178: 1223.
- Caligiuri, M.A., C. Murray, R.J. Soiffer, T.R. Klumpp, M. Seiden, K. Cochran, C. Cameron, C. Ish, L. Buchanan, D. Perillo, K. Smith and J. Ritz. 1991. Extended continuous infusion of low-dose recombinant IL-2 in advanced cancer: prolonged immunomodulation without significant toxicity. *J. Clin. Oncol.* 9: 2110.

- Caligiuri, M.A., C. Murray, M.J. Robertson, E. Wang, K. Cochran, C. Cameron, P. Schow, M.E. Ross, T.R. Klumpp, R.J. Soiffer, K.A. Smith and J. Ritz. 1993. Selective modulation of human natural killer cells *in vivo* after prolonged infusion of low dose recombinant interleukin-2. *J. Clin. Invest.* 91: 123.
- Cantor, H. and J. Jandenski. 1974. The relationship of cell division to the generation of cytotoxic activity in mixed lymphocyte culture. *J. Exp. Med.* 140: 1712.
- Chadwick, B.S., S.R. Sambhara, Y. Sasakura and R.G. Miller. 1992. Effect of class I MHC binding peptides on recognition by Natural Killer cells. *J. of Immunol.* 149: 3150.
- Chakrabarti, M., A. Bandyopadhyay and A.K. Chakravarty. 1997. Effect of oral ascorbic acid and supplementation on the hepatotoxicity and altered immune status in alcoholics without overt liver disease. (Communicated).
- Chakravarty, A.K., and W.R. Clark. 1977. Lectin-driven maturation of cytotoxic effector cells: The nature of effector memory. *J. Exp. Med.* 146: 230.
- Chakravarty, A.K. 1980. Lectin mediated activation of mouse thymus cells in ontogeny: Specificity for antigen. *Develop and Comp. Immunol.* 4: 571.
- Chakravarty, A.K., and T.K. Chaudhuri. 1983. Correlation of blastogenesis and DNA synthesis in the murine lymphocytes during *in vivo* activation with Concanavalin A. *Jap. J. of Med Sci and Biol.* 36: 43.
- Chakravarty, A.K. and S. Jha 1997. Homing of polyclonally activated syngeneic T cells at tumour site and their

efficacy in post operative immunotherapy of malignancy in mouse. *Curr. Sci.* 73: 201.

- Charmot, D., C.E. Mawas and M. Sasportes. 1975. Secondary response *in vivo* primed human lymphocytes to allogeneic reaction stimulating determinants and non specific mitogens in the generation of secondary cytotoxic effectors. *Immunogenetics.* 2: 465.
- Chaudhuri, T.K., and A. K. Chakravarty. 1981. Activation of murine thymocytes *in vivo*. Part I. Study of blastogenesis and DNA synthesis after stimulation with Concanavalin A. *J. Ind. Inst. Sci.* 63 (c): 149.
- Chaudhuri, T.K., and A. K. Chakravarty. 1983. Goat serum as substitute for fetal calf serum in *in vitro* culture murine lymphocytes. *Ind. J. Exp. Biol.* 21: 494.
- Cheever, M.A., P.D. Greenberg, A. Fefer and S. Gillis. 1982. Augmentation of the anti-tumor therapeutic efficacy of long term cultured T lymphocytes by *in vivo* administration of purified Interleukin-2. *J. Exp. Med.* 155: 968.
- Correa, I., L. Corral, D.H. Raulet. 1994. Multiple natural killer cell -activating signals are inhibited by major histocompatibility complex Class I expression in target cells. *Eur. J. of Immunol.* 24: 1323.
- Coutintio, A., E. Gronowicz and G. Moller. 1975. Signals and receptors in B cell activation. IN: *Immune recognition.* A.S. Rosenthal, ed. New York Acad. Press, pp 63.
- Das, S.K. and A.K. Chakravarty. 1997. Chromatin of primed lymphocytes exhibit differential sensitivity to DNaseI than chromatin of normal lymphocytes: suggests conformational change in packing of

- nucleohistones in primed cells. *Trans.Zool. Soc. India.* 1(1): 9.
- David, A., J. Horwitz, D. Gray, K. Ohtsuka, M. Hirokawa and T. Takahashi. 1997. The immunoregulatory effects of NK cells: the role of TGF- $\beta$  and implications for autoimmunity. *Immunol Today.* 18: 538.
- Deviere. J., C. Denys, L. Schandene, F. Remasco, M. Adler, J. Wybran and Dupen. 1988. *Clin. Exp. Immunol.* 13: 377.
- Denicoff, K.D., T.M. Durkin, M.T. Lotze. 1989. The neuroendocrine effects of interleukin-2 treatment. *J. Clin Endocrinol Metab.* 69: 402.
- Djeu, J.Y., J.A. Heinbaugh, H.T. Holden and R.B. Herberman. 1979. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. *J. Immunol.* 122: 175.
- Eberlein, T., M. Rosenstein and S.A. Rosenberg. 1982. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2. *J. Exp. Med.* 156: 385.
- Ehrlich, R., M. Efrate and I.D. Witz. 1980. IN: Natural cell mediated immunity against tumors. Herberman R.B. ed. Academic Press. pp.1073.
- Espinoza-Delgado, I., J.R. Ortaldo, R. Winkler- Pickett, K. Sugamura, L. Varesio and D.L. Longo. 1990. Expression and role of p75 Interleukin-2 receptor on human monocytes. *J. Exp. Med.* 171: 1821.
- Ettinghausen, S.E., E.M. Lipford III, J.J. Mule and S.A. Rosenberg. 1985. Recombinant Interleukin-2 stimulates *in vivo* proliferation of adoptively

- transferred lymphokine-activated killer (LAK) cells. *J. Immunol.* 135: 3623.
- Ettinghausen, S.E., and S.A. Rosenberg. 1986. Immunotherapy of murine sarcomas using lymphokine activated killer (LAK) cells: optimization of the schedule and route of administration of recombinant interleukin-2. *Cancer Res.* 46: 2784.
- Foon, K.A. 1989. Biological response modifiers: The new immunotherapy. *Cancer Res.* 49: 1621.
- Forni, G., M. Giovarelli and A. Santoni. 1985. Lymphokine - activated tumour inhibition *in vivo*. 1. The local administration of Interleukin-2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. *J. of Immunol.* 134: 1305.
- Fulton, A.M., and G.H. Heppner. 1985. Relationship of prostaglandinE and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. *Cancer Res.* 45: 4779.
- Gerson, J.M., 1980. IN: Natural cell mediated immunity against tumors. Herberman R.B. ed. Academic Press. N.Y.
- Gillis, S., and K.A. Smith. 1977. Long term culture of tumour specific cytotoxic T cells. *Nature* 268: 154.
- Gillis, S., M.M. Ferm, W.Ou and K.A. Smith. 1978. T cell growth factor: Parameters of production and a quantitative microassay for activity. *J. Immunol.* 120: 2027.
- Glimcher, L., F.W. Shen and H. Cantor. 1977. Identification of a cell-surface antigen selectively expressed on the Natural killer cell. *J. Exp. Med.* 145: 1.

- Gorelik, E., R.H. Wiltrout, K. Okumura, S. Habu and R.B. Herberman. 1982. Role of Natural Killer cells in the control of metastatic spread and growth of tumour cells in mice. *Int. J. Cancer.* 30: 107.
- Green, W.R., Z.K. Ballas, and C.S. Henney. 1978. Studies on the mechanisms of lymphocyte-mediated cytotoxicity. XI. The role of lectin in lectin-dependent cell mediated cytotoxicity. *J. Immunol.* 121: 1566.
- Grimm, E.A., A. Majumdar, H.Z. Zhang and S.A. Rosenberg. 1982. Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by Interleukin-2-activated autologous human peripheral blood lymphocytes. *J. Exp Med.* 155: 1823.
- Grimm, E.A. K.M. Ramsey, A. Majumdar, D.J. Wilson, J. Y. Djeu and S.A. Rosenberg. 1983a. Lymphokine activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes and natural killer cells. *J. Exp Med.* 157: 884.
- Grimm, E.A., R.J. Robb, J.A. Roth, L.M. Neckers, L.B. Lachman, D.J. Wilson and S.A. Rosenberg. 1983b. Lymphokine activated killer cell phenomenon III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine activated killer cells. *J. Exp Med.* 158: 1356
- Gunji, Y., N.L. Vujanovic, J.C. Hiserodt, R.B. Herberman, and E. Gorelik. 1989. Generation and characterization of purified adherent lymphokine

- activated killer cells in mice. *J. Immunol.* 142: 1748.
- Haller, O., M. Hansson, R. Kiessling and H. Wigzell. 1977. Role of nonconventional natural killer cells in resistance against syngeneic tumor cells *in vivo*. *Nature.* 270: 609.
- Hanna, N., and R. Burton. 1981. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis *in vivo*. *J. Immunol.* 121: 1754.
- Hata, K., X.R. Zhang, S. Iwatsuki, D.H. Van Thiel, R.B. Herberman, and T.L. Whiteside. 1990. Isolation, phenotyping and functional analysis of lymphocytes from human liver. *Clin. immunol. Immunopathol.* 56: 401.
- Hefeneider, S.H., P.J. Conlon, C.S. Henney and S. Gillis. 1983. *In vivo* interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident NK cells. *J. Immunol.* 180: 222.
- Heininger, D.J., M. Touton, A.K. Chakravarty and W.R. Clark. 1976. Activation of cytotoxic function in T lymphocytes. *J. Immunol.* 117: 2175.
- Hellstrom, I., and K.E. Hellstrom. 1969. Studies on cellular immunity and its serum mediated inhibition in moloney virus- induced mouse sarcomas. *Int. J. Cancer.* 4: 587.
- Hellstrom, I., and K.E. Hellstrom. 1970. Colony inhibition studies on blocking and non blocking serum effects on cellular immunity of moloney sarcomas. *Int. J. Cancer.* 5: 159..
- Hellstrom, I., and K.E. Hellstrom, and H.O. Sjogren. 1970. Serum mediated inhibition of cellular immunity to

- methylcholanthrene-induced murine sarcomas. *Cell Immunol.* 10: 18
- Hellstrom, I., G.A. Warner, K.E. Hellstrom and H O. Sjogren. 1973. Sequential studies on cell mediated tumour immunity and blocking serum activity in ten patients with malignant melanoma. *Int. J. Cancer.* 11: 280.
- Hellstrom, K.E. and I. Hellstrom. 1974. Lymphocyte mediated cytotoxicity and blocking serum activity to tumour antigens. *Adv. Immunol.* 18: 209.
- Hellstrom, I., and K.E. Hellstrom. 1979. Enhancement of tumour outgrowth by tumour associated blocking factors. *Int. J. Cancer.* 23: 366.
- Henney, C.S., K. Kuribayashi, D.E. Kern and S. Gillis. 1981. Interleukin-2 augments natural killer cell activity. *Nature.* 291: 335.
- Herberman, R.B., M.E. Nunn and D.H. Lavrin. 1975. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. 1. Distribution of reactivity and specificity. *Int. J. Cancer.* 16: 216.
- Herberman, R.B., S. Bartram, J.S. Haskill, M. Nunn, H.T. Holden and W.H. West. 1977. Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. *J. Immunol.* 119: 322.
- Herberman, R.B., and H.T. Holden. 1978. Natural cell-mediated immunity. *Adv. Cancer Res.* 27: 305.
- Herberman, R.B., T. Timonen, C. Reynolds and J.R. Ortaldo. 1980. Characteristics of NK cells IN: Natural cell mediated immunity against tumors. ed. R.B. Herberman, Academic Press, New York. pp.89.

- Herberman, R.B., 1983. Immune surveillance: updated formulation and possible effector mechanism. IN: *Progress in Immunology V.* ed. Tada T. New York. Academic Press. pp. 1157.
- Herberman, R.B., J. Hiserodt and N. Vujanovic. 1987. Lymphokine activated killer cell activity. *Immunol Today.* 8: 178.
- Herbert, W.J., 1978. Laboratory animal techniques for Immunology. IN: *Handbook of Experimental Immunology.* D. M. Weir, eds. Blackwell Scientific Publication.
- Hercend, T., and R.E. Schmidt. 1988. Characteristics and uses of Natural killer cells. *Immunol Today.* 9:291.
- Hercend, T., F. Farace, D. Baume, F. Charpentier, J.P. Droz, F. Triebel and B. Escudier. 1990. Immunotherapy with lymphokine activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma. *J. Biol Response Mod.* 9: 546.
- Hladik, F., J.A. Tratkiewicz, H. Tilg, W. Vogel, U. Schwulera, M. Kronke, W.E. Aulitzky and C. Huber. 1994. Biologic activity of low dosage IL-2 treatment *in vivo.* *J. Immunol.* 153: 1449.
- Horwitz, D.A., J.D. Gray, K. Ohtsuka, M. Hirokawa and T. Takahashi. 1997. The immunoregulatory effects of NK cells: the role of TGF- $\beta$  and implications for autoimmunity. *Immunol Today.*
- Itoh, H., T. Abo, S. Sugawara, A. Kanno and K. Kumagai. 1988. Age related variation in the proportion and reactivity of murine liver Natural Killer cells and their cytotoxicity against regenerating hepatocytes. *J. Immunol.* 141: 315.

- Jaroslav, B.N. and L. Ortiz- Ortiz. 1971. Hydroxyurea and cell cycle kinetics of cultured antibody forming cells. *Cell Immunol.* 2: 164.
- Jordan, S.O., and C.A Biron. 1996. An absolute and restricted requirement for IL-12 in natural killer cell INF- $\gamma$  production and antiviral defence. *J.Immunol.* 156: 1138.
- Julius, M., E. Simpson and A. L. Herzenberg. 1973. A rapid method for isolation of functional thymus derived murine lymphocytes. *Eur. J. Immunol.* 3: 645.
- Karlhofer, F.M., and W.M. Yokoyama. 1991. Stimulation of murine Natural killer (NK) cells by a monoclonal antibody specific for the NK 1.1 antigen. IL-2 activated NK cells possess additional specific stimulation pathways. *J. Immunol.* 146: 3662.
- Karre, K. 1992. An unexpected petition for pardon. *Curr. Biol.* 2: 673.
- Karre, K. 1995. Express yourself or die: peptides, MHC molecules and NK cells. *Science.* 267: 978.
- Karre, K., G.O. Klein, R. Kiessling, G. Klein and J.C. Roder. 1980. Low natural *in vivo* resistance to syngeneic leukemias in natural killer deficient mice. *Nature.* 284: 624.
- Kasai, A.H., W.D. Travis, L. Feinberg, S. Pillatuga, L.M. Striker, W.C. Roberts, M.T. Lotze, J.J. Yang and S.A. Rosenberg. 1990. Pathologic findings associated with interleukin-2 based immunotherapy for cancer: A post mortem study of 19 patients. *Hum. Pathol.* 21: 493.
- Kay, H.D., G.D. Bonnard, W.H. West and R.B. Herberman. 1977. A functional comparison of human Fc-receptor-bearing lymphocytes active in

natural cytotoxicity and antibody-dependent cellular cytotoxicity. *J. Immunol.* 118: 2058.

- Kiessling, R., E. Klien, H. Pross and H. Wigzell. 1975. "Natural" killer cells in the mouse I. Cytotoxic cells with specificity for mouse Moloney leukemic cells. Characteristics of the killer cell. *Eur. J. Immunol.* 5: 112.
- Kiessling R., G. Petranyi, G. Klein and H. Wigzell. 1975. Genetic variation of *in vitro* cytolytic activity and *in vivo* rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. *Int J. Cancer.* 15: 933.
- Kiessling, R., G. Petranyi, G. Klein, H. Wigzell. 1976. Non T-cell resistance against mouse Moloney lymphoma. *Int J. Cancer.* 17: 1.
- Kiessling, R., P.S. Hochman, O. Haller, G.M. Shrearer, H. Wigzell and G. Cudkowicz. 1977. Evidence for a similar or common mechanism for Natural killer cell activity and resistance to hemopoietic grafts. *Eur. J. Immunol.* 7: 655.
- Kiessling, R., and O. Haller. 1978. IN: Contemporary topics in Immunobiology, eds. N. Warner and Cooper. M(Plenums. New York). Vol 8. pp 171
- Kiessling, R., and H. Wigzell. 1979. An analysis of the murine Natural Killer cells as to structure, function and biological relevance. *Immunol. Rev.* 44: 165.
- Kimata, H., E.H. Sherr and A. Saxon. 1988. Human Natural Killer (NK) cells produce a late-acting B-cell differentiation activity. *J. Clin. Immunol.* 8: 381.

- King, Ashley., Y.W. Loke and G. Chaouat. 1997. Natural killer cells and reproduction. *Immunol Today*. 18: 64.
- Kobayashi. M., L. Fitz, M. Ryan, R.M. Hewick, S.C. Clark, S.Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of Natural Killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. *J. Exp. Med.* 170: 827.
- Kragel, A.H., W.D. Travis, L. Feinberg, S. Pillatuga, L.M. Striker, W.C. Roberts, M.T. Lotze, J.J. Yang and S.A. Rosenberg. 1990. Pathologic findings associated with Interleukin-2 based immunotherapy for cancer: A post mortem study of 19 patients. *Hum. Pathol.* 21: 493.
- Kung, S.K., and R.G. Miller. 1995. The NK 1.1 antigen in NK-mediated F1 antiparent killing *in vitro* J. *Immunol.* 154: 1624.
- Kurosawa, S., G. Matsuzaki, H. Mamaru, A. Takashi and N. Kikuo. 1993. Early appearance and activation of natural killer cells in human tumour infiltrating lymphoid cells during tumor development. *Eur.J. Immunol.* 23: 1029.
- Lafreniere, R., and S.A. Rosenberg. 1985. Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. *Cancer Res.* 45: 3735.
- Lala, P.K., V. Santer, H. Libenson and S. Parhar. 1985. Changes in host NK population in mice during tumor development. I. Kinetics and *in vivo* significance. *Cell Immunol.* 93: 250.

- Lamont, A.G., and L. Adorina. 1996. IL-12: a key cytokine in immune regulation. *Immunol. Today*. 17: 214.
- Lanier, L.L., A.M. Le, C.J. Civin, M.R. Loken and J.H. Phillips. 1986. The relationship of CD16 (Leu11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. *J. Immunol*. 136: 4480.
- Lanier, L.L., J.J. Ruttenburg, J.H. Phillips. 1988. Functional and biochemical analysis of CD16 antigen on Natural Killer cells and granulocytes. *J. Immunol*. 141: 3478.
- Lanier, L.L., and J.H. Phillips. 1992. Natural killer cells. *Curr. Opin in Immunol*. 4: 38.
- Lanier, L.L. 1995. The role of natural killer cells in transplantation. *Curr. Opin in Immunol*. 7: 625.
- Lee, R.E., M.T. Lotze, J.M. Skipper, E. Tucker, R.O. Bonow, F.B. Ognibene, J.A. Carrasquillo, J.H. Srelhamer, J.E. Parrilo and S.A. Rosenberg. 1989. Cardiorespiratory effects of immunotherapy with Interleukin-2. *J. Clin. Oncol*. 7: 7
- Liao, N., M. Bix, M. Zijlstra, R. Jaenisch and D. Raulet. 1991. *Science*. 253: 199.
- Ljunggren, H.G., and K. Karre. 1990. In search of the "missing self". MHC molecules and NK cell recognition. *Immunol. Today*. 11: 237.
- Lopez-Botet, M., L. Moretta and J. Strominger. 1996. NK-cell receptors and recognition of MHC I molecules. *Immunol Today*. 17: 212.
- Lorenzen, J., C.E. Lewis, D. Mc Cracken, E. Horak, M. Greenall and J.O'DMc Gee. 1991. Human tumor-

associated NK cells secrete increased amounts of interferon- $\gamma$  and Interleukin-4. *Br. J. Cancer.* 64: 457.

- Lotze, M.T., E.A. Grimm, A. Mazumdar, J.L. Strausser and S.A. Rosenberg. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. *Cancer Res.* 41: 4420.
- Lotze, M.T., Y.L. Matory, S.E. Ettinghausen, A.A. Rayner, S.O. Sharrow, C.A.Y. Seipp, M.C. Custer and S.A. Rosenberg. 1985. *In vivo* administration of purified human Interleukin-2. Half-life, immunologic effects and expansion of peripheral lymphoid cells *in vivo* with recombinant IL-2. *J.Immunol.* 135: 2865.
- Luini, W., D. Boraschi, S. Alberti, A. Aleotti and A. Tagliabue. 1981. Morphological characterization of a cell population responsible for natural killer activity. *Immunology.* 43: 663.
- Maitra, U.K. 1986. Immune response of activated lymphocytes to chemically induced tumor cells. *Ph D. Thesis*, University of North Bengal. India.
- Maitra, U.K., and A.K. Chakravarty. 1990. Incapacitation of fibrosarcoma cells by polyclonally activated murine T cells. *Indian. J. Exp. Biol.* 28: 308.
- Malkovsky, M., B. Loveland, M. North, G.L. Asherson, L. Gao, P. Ward and W. Fiers. 1987. Recombinant Interleukin-2 directly augments the cytotoxicity of human monocytes. *Nature.* 325: 262.
- Margolin, K.A., A.A. Rayner, M.J. Hawkins, M.B. Atkins, J.P. Dutcher, R.I. Fisher, G.R. Weiss, J.H. Doroshow, H.S. Jaffe and M. Roper. 1989. Interleukin-2 and lymphokine activated killer cell

therapy of solid tumours: analysis of toxicity and management guidelines. *J. Clin. Oncol.* 7: 486.

- Mazumdar, A., and S.A. Rosenberg. 1984. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated *in vitro* by Interleukin-2. *J. Exp. Med.* 159: 495.
- Merluzzi, V.J., D.M. Savage, R. Mertelsmann and K. Welte. 1984. Generation of non specific murine cytotoxic T cells *in vitro* by purified human interleukin-2. *Cell Immunol.* 84: 74.
- Mills, G.B., G. Carlson and V. Paetkau. 1980. Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin-2): *in vivo* activity. *J. Immunol.* 125: 1904.
- Mingari, M.C., F. Gerosa, G. Carra, R.S. Accolla, A. Moretta, R.H. Zubler, T.A. Waldman and L. Moretto. 1984. Human Interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. *Nature.* 312: 641.
- Mizutani, Y., Y. Nino, M. Fukumoto, O. Yoshida. 1994. Enhanced antitumor effect of Baccilus Calmete-Guerin in combination with fibrinogen on urinary bladder tumor. *J. Urol.* 151: 1420.
- Morgan, D.A., F.W. Ruscetti and R. Gallo. 1976. Selective *in vitro* growth of T lymphocyte from normal human bone marrow. *Science.* 193: 1007.
- Morio, T., S. Nonoyama and J. Yata. 1989. Suppression of *in vitro* immune globulin synthesis by CD16(Leu 11a)+, CD56 (NK H1, Leu19)+ non-T lineage

- NK cells; lack of suppression of cells from immunodeficient patients. *Clin. Exp. Immunol.* 78: 159.
- Morio, T., K. Takase, H. Okawa, M. Oguchi, M. Kanbara, F. Hiruma, K. Yoshino, T. Kaneko, S. Asamura, T. Inque, Y. Tsuji, H. Tasakeai, I. Kakei, K. Miyata, and J. Yata. 1989. The increase of non-MHC-restricted cytotoxic cells ( $\gamma/\delta$  -TcR bearing cells or NK cells) and the abnormal differentiation of B cells in Wiskott- Aldrich syndrome. *Clin. Immunol. Immunopathol.* 52: 279.
- Moy, P.M., E.C. Holmes and S.H. Golub. 1985. Depression of NK cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. *Cancer Res.* 45:57.
- Mule, J.J., S.Shu, S.L. Schwarz and S.A. Rosenberg. 1984. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. *Science.* 225: 1487.
- Mule, J.J., S.Shu and S.A. Rosenberg. 1985. The antitumor efficacy of lymphokine killer cells and recombinant interleukin-2 *in vivo*. *J. Immunol.* 135: 1646.
- Mule, J.J., S.E. Ettinghausen, P. J. Spiess, S. Shu and S.A. Rosenberg. 1986. Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 *in vivo*: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. *Cancer. Res.* 46: 676.
- Mule, J.J., J. Yang, S. Shu and S.A. Rosenberg. 1986. The antitumor efficacy of lymphokine activated killer cells and recombinant Interleukin-2 *in vivo*: direct correlation between reduction of established

- metastases and cytolytic activity of lymphokine-activated killer cells. *J. Immunol.* 136: 3899
- Nabel, G., W.J. Allard and H. Cantor. 1982. A cloned cell line mediating Natural killer cell function inhibits immunoglobulin secretion. *J. Exp. Med.* 156: 658.
- Nastala, C.L., H.D. Edington, T.G. Mc Kinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M.K. Gately, S.F. Wolf, R.D. Schreiber, W. J. Storkus and M.T. Lotze. 1994. Recombinant Interleukin-12 (IL-12) administration induces tumour regression in association with interferon-gamma production. *J. Immunol.* 153: 1697.
- Nedrud, J., M. Touton and W. Clark. 1975. Requirement for DNA synthesis and gene expression in the generation of cytotoxicity *in vitro*. *J. Exp. Med.* 142: 960.
- Nowotny, A. 1979. IN: Basic exercises in Immunochemistry. A Laboratory manual. Second revised and enlarged edition. Springer- Verlag- Berlin- Heidelberg, N. York.
- Oehler, J.R., L.R. Lindsay, M.E. Nunn and R.B. Herberman. 1978. Natural cell mediated cytotoxicity in rats. I. Tissue and strain distribution and demonstration of a membrane receptor for the Fc portion of IgG. *Int. J. Cancer.* 21: 204.
- Ognibene F.P., S.A. Rosenberg, M. Lotze, J. Skibber, M.M. Parker, J.H. Shelhamer and J.E. Parillo. 1988. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. *Chest* 94: 750.

- Oldham ,R.K. 1983. Biological response modifiers. *J. Natl Cancer Inst.* 70: 789
- Ottow, R.T., E. P. Steller, P. H. Sugarbaker, R. A. Wesley and S.A. Rosenberg. 1986. Immunotherapy of intraperitoneal cancer with Interleukin-2 and lymphokine-activated killer cells: reduction of tumor and survival benefits in murine models. *Cancer Res.* In Press.
- Pahwa, R., T. Chatila, S. Pahwa, C. Paradise, N.K. Day, R. Geha, S.A. Schwartz, H. Slade, N. Oyaizu and R. A. Good.1989. Recombinant Interleukin-2 therapy in severe combined immunodeficiency disease. *Proc. Natl. Acad. Sci. USA.* 86: 5069.
- Papa, M.Z., J.J. Mule and S.A. Rosenberg:1986. The antitumor efficacy of lymphokine-activated killer cells and recombinant Interleukin-2 *in vivo* successful immunotherapy of established pulmonary metastases from weakly immunogenic and non-immunogenic murine tumors of three distinct histological types. *Cancer Res.*46: 4973.
- Parkhouse, R.M.E., G. Janessy and M. F. Greaves. 1972. Selective stimulation of IgM synthesis in mouse B lymphocytes by pokeweed mitogen. *Nature.* 235: 21.
- Paul, B.N., and A.K. Chakravarty. 1988. Density of Con A receptors on T cell of bat and its implication on delayed activation. *J. Indian Inst. Sci.* 68: 37.
- Paya, C.V., N. Kenmotsu, R.A. Schoon and P.J. Leibson.1988. Tumor necrosis factor and lymphotoxin secretion by human Natural Killer cells leads to antiviral cytotoxicity. *J. Immunol.* 141: 1989.

- Pelus, L.M., and R.S. Bockman. 1979. Increased prostaglandin synthesis by macrophages from tumor bearing mice. *J. Immunol.* 123: 2118.
- Perussia, B., M.M. Tutt, W.Q. Qiu, W.A. Kuziel, P.W. Tucker, G. Trinchieri, M. Bennett, J. V. Ravetch and V. Kumar. 1989. Murine Natural Killer cells express functional Fc $\gamma$  receptor II encoded by the Fc $\gamma$ R  $\alpha$  gene. *J. Exp. Med.* 170: 73.
- Perussia B. 1991. Lymphokine- Activated Killer cells, Natural Killer cells and cytokines. *Curr Opin Immunol.* 3: 49-55.
- Peter, H.H., J. Paire-Fischer, W.H. Fridman, C. Aubert, J.P. Cesarini, R. Roubin and F.M. Kourilsky. 1975. Cell- mediated cytotoxicity *in vitro* of human lymphocytes against a tissue culture melanoma cell line (IGR3). *J. Immunol.* 115: 539.
- Procopio, A.D. G., P. Allavena and J.R. Ortaldo. 1985. Noncytotoxic functions of Natural Killer (NK) cells: large granular lymphocytes (LGL) produce a B cell growth factor (BCGF). *J. Immunol* 135: 3264.
- Raulet, D. H. and W. Held 1995. Natural Killer cell receptors. The offs and ons of Natural Killer cell recognition. *Cell.* 82:697
- Ravetch J.V. and J.P. Kinet. 1991. Fc Receptors. *Annu. Rev Immunol.* 9: 457
- Reid, L.M., C. Jones, N. Minato, B.R. Bloom and J. Holland .1979. Rejection of virus persistently infected tumor cells. 1. Rejection in athymic mice. *J. Exp. Med.* 149: 1117

- Reynolds, C.W., S.O. Sharrow, J.R. Ortaldo and R. B. Herberman. 1981. Natural killer activity in the rat. I. Isolation and characterization of the effector cells. *J.Immunol.* 127: 282
- Riccardi C., A. Santoni, T. Barlozzari, P. Puccetti and R. B. Herberman. 1980. *In vivo* natural reactivity of mice against tumor cells. *Int J. Cancer.* 25: 475
- Robles, C.P., and S.B. Pottack. 1986. Regulation of the secondary *in vitro* antibody response by endogenous natural killer cells: kinetics, isotype, preference , and non identity with T suppressor cells. *J. Immunol.* 137: 2418.
- Roder J.C. and A. K. Duwe. 1979. The beige mutation in the mouse selectively impairs Natural Killer cell function. *Nature* 278: 451
- Roder, J.C. 1980. Target-effector interactions in the Natural Killer(NK) cell system. VI. The influence of age and genotype as NK binding characteristics. *Immunology* 41:483.
- Rosenberg S.A. 1985. Lymphokine activated killer cells. A new approach to immunotherapy of cancer. *JNCL* 75: 595
- Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni and J.T. Vetto. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. *N. Engl. J. Med.* 313: 1485
- Rosenberg, S.A. 1986. Adoptive immunotherapy of cancer using lymphokine-activated killer cells and recombinant interleukin-2. IN: *The important*

- advances in Oncology* 1986. V.T.De Vita, S.Hellman and S.A. Rosenberg, eds. J.B. Lippincott, Philadelphia.P.A. pp. 55.
- Rosenberg, S.A., M.T. Lotze, L.M. Muul, A.E. Chang, F.P. Avis, S. Leitman, W.M. Lincham, C.N. Robertson, R.E. Lee, J.T. Rubin, C.A. Siapp, C.G. Simpson and D.E. White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose interleukin-2 alone. *N Engl J. Med* 316:889
- Rosenberg, S. A. 1988. The development of new immunotherapies for the treatment of cancer using Interleukin-2. *Ann Surg.* 208:121
- Rosenberg S.A. 1988. Immunotherapy of patients with advanced cancer using Interleukin-2 alone or in combination with lymphokine-activated killer cells. IN: *Important Advances in Oncology*. Ch.12. De Vita, V.T., S. Hellman and S.A. Rosenberg eds., J.B. Lippincott, Philadelphia, pp217
- Rosenberg S.A., M.T. Lotze, J.C. Yang, S. L. Topalain, A.E. Chang, D.J. Schwartzentruber, P. Aebersold, S. Leitman, W.M. Linchan, C.A. Scipp, D.E. White and S.M. Steinberg. 1993. Prospective randomized trial of high-dose Interleukin-2 or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J. Natl Cancer Inst.* 85: 622
- Rosenstein, M., I. Yron, Y. Kaufmann and S.A. Rosenberg. 1984. Lymphokine activated killer cells: lysis of fresh syngeneic natural killer resistant murine tumor cells by lymphocytes cultured in Interleukin-2. *Cancer Res.* 44:1946.

- Rosenstein, M., S.E. Ettinghausen and S.A. Rosenberg 1986. Extravasation of intravascular fluid mediated by the systemic administration of recombinant Interleukin-2 *Immunol.* 137: 1735
- Roychowdhury M. 1995. Study of immune status in hepatic disorders and effect of ascorbic acid and zinc supplement. *Ph D. Thesis.* University of North Bengal, Siliguri, India.
- Ryan, J., E. Niemi, M. Nakamura, W. Seaman. 1995. NKR-PIA is a target-specific receptor that activates natural killer cell cytotoxicity. *J. Exp. Med.* 181: 1911.
- Saksela, E., T. Timonen, A. Ranki and P. Hayry. 1979. Fractionation, morphological and functional characterization of effector cells responsible for human Natural Killer activity of fetal fibroblasts and cell line targets. *Immunol Rev.* 44: 71.
- Salup R.R. and R.H. Wiltrout 1986. Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2 stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease. *Cancer Immunol. Immunother.* 22:31.
- Santoli, D., G. Trinchieri and F.S. Leifn. 1978. Cell mediated cytotoxicity against virus-infected target cells in human. I. Characterization of the effector lymphocytes. *J. immunol.* 121: 526.
- Santoli, D., G. Trinchieri and H. Koprowski. 1978. Cell mediated cytotoxicity in humans against virus-infected target cells. II. Interferon induction and activation of Natural Killer cells. *J. Immunol.* 121: 532

- Scala, G., P. Allavena, J.Y. Djeu, T. Kasahara, J.R. Ortaldo, R.B. Herberman and J.J. Oppenheim. 1984. Human large granular lymphocytes are potent producers of Interleukin-2. *Nature*. 309:56.
- Schwartzentruber D, M. T. Lotze and S.A. Rosenberg .1988. Colonic perforation. An unusual complication of therapy with high dose Interleukin-2. . 62: 2350.
- Scott, Phillips and G. Trinchieri. 1995. The role of Natural Killer cells in host- parasite interactions. *Curr. Opin in Immunol*. 7: 34
- Sendo, F., T. Aoki, E.A. Boyse and C.K. Bufo. 1975. Natural occurrence of lymphocytes showing cytotoxic activity to Balb/c radiation- induced leukemia RLO cells. *J. Nat. Cancer Inst*. 55: 603
- Sentman, C.L., J. Hackett , V. Kumar and M. Bennett.1989. Identification of a subset of murine Natural Killer cells that mediates rejection of Hh-1<sup>d</sup> but not Hh-1<sup>b</sup> bone marrow grafts. *J. Exp Med* . 170: 191.
- Shortman, K., W.J. Byrd, J.C. Cerottini and K.J. Brunner. 1973. Characterization and separation of mouse lymphocyte subpopulation responding to PHA and PWM. *Cell Immunol*. 6: 251.
- Shu, S.Y., T. Chou and K. Sakai. 1989. Lymphocytes generated by *in vivo* priming and *in vitro* sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. *J. Immunol*. 143: 740.
- Siegel, J.P. and R.K. Puri. 1991. Interleukin-2. Toxicity. *J. Clin Oncol*. 9: 693
- Smith K.A.. 1988. Interleukin-2; inception, impact and implications *Science* (Wash. D.C.). 240: 1169

- Smith, K.A. 1989. The Interleukin-2 receptor. *Ann. Rev. Cell. Biol.* 5: 397.
- Smith K.A. 1992. Interleukin-2. *Curr. Opin in Immunology* 4:271.
- Sprent, J., and J.F. Miller. 1976. Fate of H2-activated T lymphocytes in syngeneic hosts. III. Differentiation into long-lived recirculating memory cells. *Cell Immunol.* 21: 314.
- Sprent, J., D.F. Tough. 1994. Lymphocyte life-span and memory. *Science.* 265: 1395.
- Stobo, J.D., and W.E. Paul. 1973. Functional heterogeneity of murine lymphoid cell III. Differential responsiveness of T cell to phytohaemagglutinin and Concanavalin A as probe for T cell subsets. *J. Immunol.* 110: 362.
- Stuttman, O., E.G. Figarella and R. Wisur. 1980. IN: Natural killer cell mediated immunity against tumors. Herberman eds. Academic Press. N.Y., pp 997.
- Stuttman Osias. 1981. Natural Killer cells, anti-tumor surveillance and Interleukins. *Immunol Today.* 2: 205.
- Sulitzeanu D. 1993. Immunosuppressive factors in human cancer. *Adv. Cancer Res.* 60: 247.
- Tahara.H., H.J.Zeh and W.J. Storkers III. 1994. Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma *in vivo*. *Cancer Res.* 54: 182.
- Targan,S., J. Brieva, W. Newman and R. Stevens. 1985. Is the lytic process involved in the mechanism of NK

- suppression of antibody producing cells?  
*J. Immunol.* 134: 666.
- Talmadge, J., K. Meyers, D. Prieur and J. Starkey.** 1980.  
Role of Natural Killer cells in tumor growth and metastasis in beige mice. *Nature (Lond.)* 284: 622.
- Thews, A., M. Kessler, M. Wilhelm, E. Huland, C. Peschel, C. Huber, J. Lorenz and W.E. Aulitzky.** 1993.  
Aerosolized natural IL-2 for treatment of advanced malignancy : results of a phase I trial . *Ann. Hematol*, 675 : 125.
- Thijs, L.G., C.E. Hack, R.J.M. Strack, van Schijndel, J.H. Nuijens, G.J. Wolbink, A.J.M. Eerenberg-Belmer, H. van der Vall and J. Wagstaff.** 1990.  
Activation of the complement system during immunotherapy with recombinant IL-2: relation to the development of side effects. *J. Immunol.* 144:2419.
- Timonen, T., A. Ranki, E. Saksela and P. Hayry.** 1979a.  
Human Natural killer cell mediated cytotoxicity against fetal fibroblasts. III. Morphological and functional characterization of the effector cells. *Cell. Immunol.* 48: 121.
- Timonen, T., E. Saksela, A. Ranki and P. Hayry.** 1979b.  
Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity to fetal fibroblasts and cell line targets. *Immunol. Rev.* 44:71.
- Timonen, T., and E. Saksela.** 1980. Isolation of human Natural Killer cells by density gradient centrifugation. *J. Immunol. Methods.* 36:285.
- Timonen, T., J.R. Ortaldo and R.B. Herberman.** 1981.  
Characteristics of human large granular

- lymphocytes and relationship to Natural Killer and K cells. *J. Exp. Med.* 153: 569.
- Trinchieri. G., P. Bauman, M.de Marchi and Z Tokes.** 1975. Antibody-dependent cell mediated cytotoxicity in humans. *J. Immunol.* 115: 249.
- Trinchieri,G and D. Santoli.** 1978. Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. *J. Exp. Med.* 147: 1314
- Trinchieri G., M. Matsumoto- Kobayashi, S.C. Clark, J. Sheehra, L. London and B. Perussia.** 1984. Response of resting human peripheral blood natural killer cells to Interleukin-2. *J. Exp. Med.* 160: 1147
- Trinchieri G.**1989. Biology of Natural Killer cells. *Adv Immunology.* 47: 187.
- Tutt, M.M., W.A. Kuziel, J. Hackett, Jr. M.Bennett, P.W. Tucker and V. Kumar.** 1986. Murine Natural killer cells do not express functional transcripts of the  $\alpha$ -, $\beta$ - or  $\gamma$ - chains of the T cell receptor. *J. Immunol.* 137: 2998.
- Vanky, F., P. Wang and E. Klein.** 1992. The polysaccharide K (PSK) potentiates *in vitro* activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells. *Cancer Immunol Immunother.*35: 193.
- Voss, SD., R.G. Robb, G. Weil-Hillman, J.A. Hank, K. Sugamura, M. Tsudo and P. Sondel.**1990. Increased expression of the Interleukin-2 (IL-2) receptor  $\beta$  chain (p70) on CD 56<sup>+</sup> NK cells after *in*

- in vivo* IL-2 therapy.: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. *J. Exp. Med.* 172: 1101.
- Vyakarnam, A., M.K. Brenner, J. E. Reittie, C.H. Houliker and P.J. Lachmann. 1985. Human clones with Natural Killer function can activate B cells and secrete B cell differentiation factor. *Eur J. Immunol.* 15: 606.
- Wang H.M., and K.A. Smith. 1987. The Interleukin-2 receptor. Functional consequences of its biomolecular structure. *J. Exp Med.* 166: 1055
- Warner, N.L., M. F. Woodruff and R. C. Burton. 1977. Inhibition of the growth of lymphoid tumors in syngeneic athymic (nude) mice. *Int. J. Cancer.* 20: 146.
- Waterfield, J.D., E.M. Waterfield and G. Moller. 1975. Lymphocyte mediated cytotoxicity against tumour cells. I. Con A activated cytotoxic effector cells exhibit immunological specificity. *Cell Immunol.* 17: 392.
- Waterfield, J.D., and E.M. Waterfield. 1976. Lymphocyte mediated cytotoxicity against tumour cells. II. Characteristics and tissue distribution of Concanavalin A activated cytotoxic effector cells. *Eur. J. Immunol.* 6: 309.
- Watson, J., D. Mochizuki and S. Gillis. 1980. T-cell growth factors: Interleukin-2. *Immunol Today.* 1: 113.
- Watson, G.A., X. Fu and D.M. Lopez. 1991. Splenic macrophages from tumor-bearing mice coexpressing Mac-1 and Mac-2 antigens exert immunoregulatory functions via two distinct mechanisms. *J. Leuk. Biol.* 49: 126.

- Weinberg, K., and R. Parkman. 1990. Severe combined immunodeficiency due to a specific defect in the production of Interleukin-2. *N. Engl. J. Med.* 322: 1718
- Weindruch, R., B.H. Devens, H.V. Ruff and R. L. Walford. 1983. Influence of dietary restriction and aging on Natural Killer cell activity in mice. *J. Immunol.* 130: 993.
- Welsh R.M. and R.M. Zinkernagel. 1977. Heterospecific cytotoxic cell activity induced during the first three days of acute lymphocytic choriomeningitis virus infection in mice. *Nature.* 268: 646.
- West, W.H., G.B. Cannon, H.D. Kay, G.D. Bonnard and R.B. Herberman. 1976. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: Characterization of effector cell. *J. Immunol.* 118: 355.
- Whiteside, T.L., and R.B. Herberman. 1990. Characteristics of Natural Killer cells and lymphokine-activated killer cells: their role in the biology and treatment of human cancer. *Hum. Cancer Immunol.* 10:663.
- Whiteside, T.L., J. Bryant, R. Day and R.B. Herberman 1990. Natural Killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. *J. Clin. Lab Anal.* 2:102
- Whiteside, T.L., and R.B. Herberman. 1995. The role of Natural Killer cells in immune surveillance of cancer. *Curr. Opin. In Immunology.* 7: 704
- Wilder, A. Julie, C. Y. Koh and D. Yuan. 1996. The role of Natural Killer cells during *in vivo* antigen-specific antibody response. *J. Immunol.* 156: 146.

- Wiltrout, R.H., B.J.Mathieson, J.E. Talmadge, C.W. Reynolds, S. Zhang, R.B. Herberman and J.R. Ortaldo. 1984. Augmentation of organ-associated natural killer activity by biological response modifiers. *J. Exp. Med.* 160: 1431.
- Yasumaura, S., W. Lin, H. Hirabayashi, N.L. Vujanovic, R.B. Herberman and T.L. Whiteside. 1994. Immunotherapy of liver metastases of human gastric carcinoma with IL-2 activated Natural Killer cells. *Cancer Res.* 54: 3808.
- Yokoyama, W.H., 1995. Natural Killer cell receptors. *Curr. Opin. Immunol.* 7: 110.

From the diversity  
of  
Raja Ramohanthan